On Tuesday, Novavax, Inc (NASDAQ: NVAX) was -3.38% drop from the session before settling in for the closing price of $6.8. A 52-week range for NVAX has been $5.01 – $11.55.
Annual sales at Healthcare sector company grew by 25.88% over the past five years. When this article was written, the company’s average yearly earnings per share was at 272.68%. With a float of $148.32 million, this company’s outstanding shares have now reached $162.47 million.
Novavax, Inc (NVAX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 8.73%, while institutional ownership is 60.62%. The most recent insider transaction that took place on May 19 ’25, was worth 75,883. Before that another transaction happened on Apr 14 ’25, when Company’s Former Director proposed sale 4,000 for $6.10, making the entire transaction worth $24,406.
Novavax, Inc (NVAX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.52 earnings per share (EPS) during the time that was less than consensus figure (set at -0.51) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 272.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 36.29% during the next five years compared to 25.88% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.77, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach 0.02 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Novavax, Inc (NASDAQ: NVAX) saw its 5-day average volume 4.77 million, a negative change from its year-to-date volume of 6.22 million. As of the previous 9 days, the stock’s Stochastic %D was 6.30%.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 7.70%, which indicates a significant increase from 2.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.37 in the past 14 days, which was lower than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.30, while its 200-day Moving Average is $7.51. Nevertheless, the first resistance level for the watch stands at $6.69 in the near term. At $6.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.89. If the price goes on to break the first support level at $6.49, it is likely to go to the next support level at $6.40. Assuming the price breaks the second support level, the third support level stands at $6.28.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are 162,499K outstanding shares of the company, which has a market capitalization of 1.07 billion. As of now, sales total 682,160 K while income totals -187,500 K. Its latest quarter income was 70,450 K while its last quarter net income were -202,380 K.
